PT2812341T - Inibidores c-terminal de hsp90 - Google Patents
Inibidores c-terminal de hsp90Info
- Publication number
- PT2812341T PT2812341T PT137068227T PT13706822T PT2812341T PT 2812341 T PT2812341 T PT 2812341T PT 137068227 T PT137068227 T PT 137068227T PT 13706822 T PT13706822 T PT 13706822T PT 2812341 T PT2812341 T PT 2812341T
- Authority
- PT
- Portugal
- Prior art keywords
- hsp90 inhibitors
- terminal hsp90
- terminal
- inhibitors
- hsp90
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597004P | 2012-02-09 | 2012-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2812341T true PT2812341T (pt) | 2019-11-22 |
Family
ID=47754998
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT191935766T PT3656758T (pt) | 2012-02-09 | 2013-02-08 | Intermediários para a preparação de inibidores do cterminal de hsp90 |
| PT137068227T PT2812341T (pt) | 2012-02-09 | 2013-02-08 | Inibidores c-terminal de hsp90 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT191935766T PT3656758T (pt) | 2012-02-09 | 2013-02-08 | Intermediários para a preparação de inibidores do cterminal de hsp90 |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US9422320B2 (pt) |
| EP (2) | EP2812341B1 (pt) |
| JP (1) | JP6121450B2 (pt) |
| KR (1) | KR102124109B1 (pt) |
| CN (2) | CN107474085B (pt) |
| AU (1) | AU2013216858C1 (pt) |
| BR (1) | BR112014019704B1 (pt) |
| CA (1) | CA2866814C (pt) |
| CY (1) | CY1122358T1 (pt) |
| DK (2) | DK3656758T3 (pt) |
| EA (1) | EA027147B1 (pt) |
| ES (1) | ES2755093T3 (pt) |
| FI (1) | FI3656758T3 (pt) |
| HK (2) | HK1205131A1 (pt) |
| HR (1) | HRP20191940T1 (pt) |
| HU (1) | HUE046939T2 (pt) |
| LT (2) | LT3656758T (pt) |
| MX (1) | MX361233B (pt) |
| NZ (1) | NZ629778A (pt) |
| PL (1) | PL2812341T3 (pt) |
| PT (2) | PT3656758T (pt) |
| RS (1) | RS59719B1 (pt) |
| SI (1) | SI2812341T1 (pt) |
| WO (1) | WO2013119985A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2812341B1 (en) | 2012-02-09 | 2019-08-28 | The University of Kansas | C-terminal hsp90 inhibitors |
| US9994556B2 (en) | 2014-06-13 | 2018-06-12 | University Of Kansas | Triazole modified coumarin and biphenyl amide-based HSP90 inhibitors |
| KR102536408B1 (ko) * | 2014-06-24 | 2023-05-23 | 더 유니버시티 오브 캔사스 | Hsp90 저해제 및 hsp70 유도제로서의 개질된 에터기를 가진 바이페닐 아마이드 |
| WO2016145219A1 (en) * | 2015-03-10 | 2016-09-15 | University Of Florida Research Foundation, Inc. | Treatment of peripheral neuropathies |
| EP3749675A1 (en) | 2018-02-07 | 2020-12-16 | Reata Pharmaceuticals, Inc. | Co-crystal forms of a novobiocin analog and proline |
| KR20210021457A (ko) * | 2018-05-14 | 2021-02-26 | 리아타 파마슈티컬즈, 아이엔씨. | 열충격 단백질 경로와 연관된 질환의 치료를 위한 변형된 당기를 가진 바이아릴 아마이드 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010096650A1 (en) | 2009-02-20 | 2010-08-26 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| CA2585091C (en) | 2004-11-03 | 2016-07-19 | University Of Kansas | Novobiocin analogues as anticancer agents |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| WO2007095586A2 (en) * | 2006-02-14 | 2007-08-23 | The Trustees Of Columbia University In The City Of New York | Neuronal pain pathway modulators |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2008061108A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Phthalazine derivatives |
| MY148860A (en) | 2007-03-20 | 2013-06-14 | Curis Inc | Fused amino pyridine as hsp90 inhibitors |
| US7960353B2 (en) * | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| WO2011041593A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| JPWO2012008435A1 (ja) | 2010-07-13 | 2013-09-09 | 大日本住友製薬株式会社 | ビアリールアミド誘導体またはその薬理学的に許容される塩 |
| CN101967125B (zh) * | 2010-10-08 | 2012-07-04 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用 |
| EP2694506B1 (en) | 2011-04-05 | 2017-09-20 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| WO2012162054A1 (en) | 2011-05-20 | 2012-11-29 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
| EP2812341B1 (en) | 2012-02-09 | 2019-08-28 | The University of Kansas | C-terminal hsp90 inhibitors |
| US10689344B2 (en) | 2013-11-07 | 2020-06-23 | University Of Kansas | Biphenylamide derivative Hsp90 inhibitors |
| CA2929243C (en) | 2013-11-11 | 2022-05-03 | The University Of Kansas | Coumarin based hsp90 inhibitors with urea and ether substituents |
| US9994556B2 (en) | 2014-06-13 | 2018-06-12 | University Of Kansas | Triazole modified coumarin and biphenyl amide-based HSP90 inhibitors |
| KR102536408B1 (ko) | 2014-06-24 | 2023-05-23 | 더 유니버시티 오브 캔사스 | Hsp90 저해제 및 hsp70 유도제로서의 개질된 에터기를 가진 바이페닐 아마이드 |
-
2013
- 2013-02-08 EP EP13706822.7A patent/EP2812341B1/en active Active
- 2013-02-08 WO PCT/US2013/025387 patent/WO2013119985A1/en active Application Filing
- 2013-02-08 AU AU2013216858A patent/AU2013216858C1/en active Active
- 2013-02-08 EA EA201491496A patent/EA027147B1/ru unknown
- 2013-02-08 MX MX2014009608A patent/MX361233B/es active IP Right Grant
- 2013-02-08 LT LTEP19193576.6T patent/LT3656758T/lt unknown
- 2013-02-08 LT LT13706822T patent/LT2812341T/lt unknown
- 2013-02-08 KR KR1020147025348A patent/KR102124109B1/ko active IP Right Grant
- 2013-02-08 PL PL13706822T patent/PL2812341T3/pl unknown
- 2013-02-08 BR BR112014019704-0A patent/BR112014019704B1/pt active IP Right Grant
- 2013-02-08 EP EP19193576.6A patent/EP3656758B1/en active Active
- 2013-02-08 JP JP2014556739A patent/JP6121450B2/ja active Active
- 2013-02-08 DK DK19193576.6T patent/DK3656758T3/da active
- 2013-02-08 HU HUE13706822A patent/HUE046939T2/hu unknown
- 2013-02-08 SI SI201331622T patent/SI2812341T1/sl unknown
- 2013-02-08 RS RS20191454A patent/RS59719B1/sr unknown
- 2013-02-08 DK DK13706822T patent/DK2812341T3/da active
- 2013-02-08 FI FIEP19193576.6T patent/FI3656758T3/fi active
- 2013-02-08 CA CA2866814A patent/CA2866814C/en active Active
- 2013-02-08 US US14/377,616 patent/US9422320B2/en active Active
- 2013-02-08 NZ NZ629778A patent/NZ629778A/en unknown
- 2013-02-08 CN CN201710729038.6A patent/CN107474085B/zh active Active
- 2013-02-08 PT PT191935766T patent/PT3656758T/pt unknown
- 2013-02-08 ES ES13706822T patent/ES2755093T3/es active Active
- 2013-02-08 CN CN201380019057.XA patent/CN104271587B/zh active Active
- 2013-02-08 PT PT137068227T patent/PT2812341T/pt unknown
-
2015
- 2015-06-19 HK HK15105894.9A patent/HK1205131A1/xx unknown
-
2016
- 2016-08-03 US US15/227,230 patent/US10030041B2/en active Active
-
2018
- 2018-06-12 HK HK18107629.4A patent/HK1249519A1/zh unknown
- 2018-06-26 US US16/018,401 patent/US10590157B2/en active Active
-
2019
- 2019-10-24 HR HRP20191940TT patent/HRP20191940T1/hr unknown
- 2019-11-11 CY CY20191101180T patent/CY1122358T1/el unknown
-
2020
- 2020-02-05 US US16/783,025 patent/US10882881B2/en active Active
- 2020-12-04 US US17/112,060 patent/US11390640B2/en active Active
-
2022
- 2022-07-12 US US17/863,135 patent/US20230102047A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL236251B (en) | Transition execution of facility instructions: non-transitional storage | |
| EP2857033A4 (en) | SKIN-PUNKING PEPTIDE | |
| HK1207366A1 (en) | Thiadiazolidinediones as gsk-3 inhibitors gsk-3 | |
| EP2812347A4 (en) | AUTOPHAGIA-INDUCING PEPTIDE | |
| HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 | |
| HK1209105A1 (en) | Vegfr3 inhibitors vegfr3 | |
| HK1205131A1 (en) | C-terminal hsp90 inhibitors hsp90 c | |
| HK1209104A1 (en) | Vegfr3 inhibitors vegfr3 | |
| GB201009853D0 (en) | HSP90 inhibitors | |
| HK1209138A1 (en) | Peptides | |
| ZA201503275B (en) | Transporter | |
| GB201200555D0 (en) | Peptide | |
| GB201204868D0 (en) | Peptides | |
| EP2891663A4 (en) | PEPTIDE DERIVED FROM PSF1 | |
| GB201221414D0 (en) | Trans-locating peptide | |
| GB201200624D0 (en) | Peptide | |
| GB201200623D0 (en) | Peptide | |
| GB201220328D0 (en) | Peptides | |
| GB201220529D0 (en) | No details available | |
| GB201211740D0 (en) | Peptides | |
| GB201207895D0 (en) | Peptides | |
| GB201200509D0 (en) | Peptides |